Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.
about
Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactionsMutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodiesVesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistryInhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease modelsGait dynamics in mouse models of Parkinson's disease and Huntington's disease.Evaluation of Models of Parkinson's DiseaseMitochondrial dysfunction and oxidative stress in Parkinson's diseaseProtein degradation pathways in Parkinson's disease: curse or blessingNovel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's diseaseThe contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's diseaseVacuolar Protein Sorting Genes in Parkinson's Disease: A Re-appraisal of Mutations Detection Rate and Neurobiology of DiseaseThe protease Omi regulates mitochondrial biogenesis through the GSK3β/PGC-1α pathwayMitochondrial fragmentation in neurodegenerationGene-environment interactions: key to unraveling the mystery of Parkinson's diseaseResistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activationPale body-like inclusion formation and neurodegeneration following depletion of 26S proteasomes in mouse brain neurones are independent of α-synucleinPartial complex I deficiency due to the CNS conditional ablation of Ndufa5 results in a mild chronic encephalopathy but no increase in oxidative damage.Depletion of canonical Wnt signaling components has a neuroprotective effect on midbrain dopaminergic neurons in an MPTP-induced mouse model of Parkinson's diseaseModelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT scoreMPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease.Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice.Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.Role of the ubiquitin proteasome system in Parkinson's disease.Strengths and limitations of genetic mouse models of Parkinson's disease.Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data.Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze?Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.Mitochondrial glutathione, a key survival antioxidant.The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition.Neuroproteomics as a promising tool in Parkinson's disease research.Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degenerationCombination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.Proteasome inhibitor-induced apoptosis is mediated by positive feedback amplification of PKCdelta proteolytic activation and mitochondrial translocation.Lewy bodies.
P2860
Q24311624-551B407A-CFEA-4262-9FBB-26561D00D1A6Q24318474-EE2F55C3-2A21-414C-ADD0-E3269EFB80A9Q24601233-1734315F-9DF1-45F1-A389-DD5803E33301Q24673667-DF5725F7-11BC-4268-B7D0-49A05DE19E97Q24812417-9E95CB5E-310A-4107-9083-66FA9E0E5E17Q26772843-2016C64F-87E5-427C-A4D7-79914B02D3C1Q27014051-0C2A3DF1-6391-45E6-BA53-C2AC1577C2D5Q27026029-7009F406-BC4A-436D-8A7C-658659BB9722Q27301283-4A231557-ED5C-476A-A739-46BE94BFDC13Q28068464-A654DE5B-4619-4E21-A0DD-4246B1BF1D10Q28074841-388B2C38-D0FF-42EE-ADCA-EE9421F53184Q28117215-15C264AD-C425-4830-A44A-BF9C12F49BA1Q28284588-13F40208-B527-4887-9511-650A10115120Q28388674-8E8AC596-40C4-4CDC-9400-DF93FBF9D6C6Q28477043-6DACE616-3A5D-4423-91B8-FBD775A22E3DQ28585769-43C1B4F8-9A1A-44BA-93C8-2817B17F7F10Q28587077-1AA293BF-9B63-409E-B107-DCDF0C19E2E7Q28593498-8E83CB46-5E8E-475A-8308-6F02146B0213Q29048624-16EB7C04-93EA-427B-9DC1-45ED6675B4FDQ30502685-1A6B0AD6-0829-4C6B-8525-092E49F6AA04Q30540027-4F2D821B-A2A4-4116-B232-7E9565D4714DQ30544278-B140B583-33C2-4901-8976-CE7DE89068ACQ30895929-BF9AA227-D057-4E59-A6C6-DFA0317DCEA5Q33307874-84612B80-293A-4346-8F8B-3F3FFFB09D90Q33347250-30451725-F899-4F44-A1C1-AE35197A7069Q33365370-CAC7C40D-3C1F-4C33-B367-EC0FF1FC9C5EQ33392127-01E50F7C-E514-4D53-A24B-3B22107FB768Q33394700-730AE504-B8FA-400F-B4FF-77FD4F10D19BQ33457162-CC67D3E2-CEE2-41DA-8E54-7B4F5DDE9440Q33507513-DE4D7743-0806-4DE1-96F6-8C2A0665BA5FQ33649876-1F42FF2A-9919-418E-BB56-C41601BB4415Q33748087-0E09B4A3-B1DB-42FA-840C-E68170C7E1B5Q33821316-29171F4D-8698-46D7-811A-2D46B1D4FDF0Q33828847-CDC3E37F-4F32-43FD-AF0A-A79B3F9500FAQ33837238-C1DE8F6A-C2DB-490A-992A-7FBD5DC045B4Q33840243-87FD9827-D39E-47A8-B29C-40EF07CD383DQ33906753-AE2BF5C4-917B-49F9-A343-B57B55D898F3Q34085167-A2B62C67-5421-4D8D-86D1-3A748F33D065Q34214022-28A0B8EC-425C-4153-9727-1D542D0CB555Q34478663-8AB38751-EABD-448A-A993-5CAB632C2F6F
P2860
Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Parkinson-like syndrome induce ...... ome system and alpha-synuclein
@nl
Parkinson-like syndrome induce ...... me system and alpha-synuclein.
@ast
Parkinson-like syndrome induce ...... me system and alpha-synuclein.
@en
type
label
Parkinson-like syndrome induce ...... ome system and alpha-synuclein
@nl
Parkinson-like syndrome induce ...... me system and alpha-synuclein.
@ast
Parkinson-like syndrome induce ...... me system and alpha-synuclein.
@en
prefLabel
Parkinson-like syndrome induce ...... ome system and alpha-synuclein
@nl
Parkinson-like syndrome induce ...... me system and alpha-synuclein.
@ast
Parkinson-like syndrome induce ...... me system and alpha-synuclein.
@en
P2093
P2860
P50
P921
P356
P1476
Parkinson-like syndrome induce ...... me system and alpha-synuclein.
@en
P2093
Antonio Paparelli
Antonio Pellegrini
Fabrizio Pontarelli
Marco Gesi
Oliver M Schlüter
Stefano Ruggieri
P2860
P304
P356
10.1073/PNAS.0409713102
P407
P50
P577
2005-02-16T00:00:00Z